WO2003061577A8 - Polyalkylene glycol with moiety for conjugating biologically active compound - Google Patents
Polyalkylene glycol with moiety for conjugating biologically active compoundInfo
- Publication number
- WO2003061577A8 WO2003061577A8 PCT/US2003/001559 US0301559W WO03061577A8 WO 2003061577 A8 WO2003061577 A8 WO 2003061577A8 US 0301559 W US0301559 W US 0301559W WO 03061577 A8 WO03061577 A8 WO 03061577A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polyalkylene glycol
- biologically active
- moiety
- active compound
- conjugating biologically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Abstract
Priority Applications (38)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ534708A NZ534708A (en) | 2002-01-18 | 2003-01-17 | Polyalkylene glycol with moiety for conjugating biologically active compound |
MXPA04006855A MXPA04006855A (en) | 2002-01-18 | 2003-01-17 | Polyalkylene polymer compounds and uses thereof. |
EP15203017.7A EP3025726B1 (en) | 2002-01-18 | 2003-01-17 | Polyalkylene polymer compounds and uses thereof |
BRPI0306993A BRPI0306993B8 (en) | 2002-01-18 | 2003-01-17 | activated polyalkylene glycol polymer; composition; and use of a compound in the production of a drug for the treatment of multiple sclerosis or susceptible viral infection. |
DK03731987.8T DK1476181T3 (en) | 2002-01-18 | 2003-01-17 | POLYALKYLENE POLYMER COMPOUNDS AND USE THEREOF |
ES03731987.8T ES2566797T3 (en) | 2002-01-18 | 2003-01-17 | Polyalkylene polymer compounds and uses thereof |
EP19203313.2A EP3669887A1 (en) | 2002-01-18 | 2003-01-17 | Polyalkylene polymer compounds and uses thereof |
UA20040706173A UA82184C2 (en) | 2002-01-18 | 2003-01-17 | Polyalkylene glycol with residue for conjugation of bioactive compound |
MEP-2008-356A ME00239B (en) | 2002-01-18 | 2003-01-17 | Polyalkylene polymer compounds and uses thereof |
JP2003561523A JP2005526151A (en) | 2002-01-18 | 2003-01-17 | Polyalkylene glycols having moieties for the binding of biologically active compounds |
YU63504A RS55578B1 (en) | 2002-01-18 | 2003-01-17 | Polyalkylene polymer compounds and uses thereof |
SI200332472A SI1476181T1 (en) | 2002-01-18 | 2003-01-17 | Polyalkylene polymer compounds and uses thereof |
EA200400962A EA009783B1 (en) | 2002-01-18 | 2003-01-17 | Polyalkylene glycolhaving a moiety for conjugation of a biologically active compound |
KR1020047011171A KR100964411B1 (en) | 2002-01-18 | 2003-01-17 | Polyalkylene glycol with moiety for conjugating biologically active compound |
CA2473526A CA2473526C (en) | 2002-01-18 | 2003-01-17 | Polyalkylene polymer compounds and uses thereof |
HU0500457A HU230473B1 (en) | 2002-01-18 | 2003-01-17 | Polyalkylene polymer compounds and the use thereof |
SK310-2004A SK3102004A3 (en) | 2002-01-18 | 2003-01-17 | Polyalkylene polymer compounds and uses thereof |
EEP200400105A EE05509B1 (en) | 2002-01-18 | 2003-01-17 | Activated pol alk leengl kolpolmer and compositions containing it |
EP03731987.8A EP1476181B1 (en) | 2002-01-18 | 2003-01-17 | Polyalkylene polymer compounds and uses thereof |
AU2003210564A AU2003210564B2 (en) | 2002-01-18 | 2003-01-17 | Polyalkylene glycol with moiety for conjugating biologically active compound |
MEP-356/08A MEP35608A (en) | 2002-01-18 | 2003-01-17 | Polyalkylene polymer compounds and uses thereof |
IL163006A IL163006A (en) | 2002-01-18 | 2004-07-14 | Polyalkylene glycol polymers and conjugates thereof with biologically active compounds |
IS7353A IS2989B (en) | 2002-01-18 | 2004-07-15 | Polyalkylene polymer compounds and their benefits |
US10/892,830 US8017733B2 (en) | 2002-01-18 | 2004-07-16 | Polyalkylene polymer compounds and uses thereof |
BG108839A BG66525B1 (en) | 2002-01-18 | 2004-08-10 | Polyalkyleneglycol with residue for conjugation with biologically active compound |
NO20043422A NO339857B1 (en) | 2002-01-18 | 2004-08-17 | Conjugate containing polyalkylene glycol, pharmaceutical composition containing same and use of same for the treatment of disease |
ZA2004/06555A ZA200406555B (en) | 2002-01-18 | 2004-08-17 | Polyalkylene glycol with moiety for conjugating biologically active compound |
HK05103877.7A HK1072721A1 (en) | 2002-01-18 | 2005-05-09 | Polyalkylene polymer compounds and uses thereof () |
US13/230,080 US8524660B2 (en) | 2002-01-18 | 2011-09-12 | Polyalkylene polymer compounds and uses thereof |
US14/015,711 US20150246097A9 (en) | 2002-01-18 | 2013-08-30 | Polyalkylene Polymer Compounds and Uses Thereof |
NO20151082A NO344612B1 (en) | 2002-01-18 | 2015-08-26 | Pharmaceutical composition comprising interferon beta (IFN β) and conjugate comprising reaction products of an activated polyalkylene glycol polymer and a process for their preparation. |
LU93162C LU93162I2 (en) | 2002-01-18 | 2016-08-03 | Peg interferon beta-1a or a pharmaceutically acceptable derivative thereof (PLEGRIDY) |
BE2016C040C BE2016C040I2 (en) | 2002-01-18 | 2016-08-04 | |
CY2016027C CY2016027I2 (en) | 2002-01-18 | 2016-08-05 | POLYALKYLENE POLYMER COMPOUNDS AND USES THEREOF |
NL300826C NL300826I2 (en) | 2002-01-18 | 2016-08-11 | |
US15/237,064 US20170049904A1 (en) | 2002-01-18 | 2016-08-15 | Polyalkylene polymer compounds and uses thereof |
NO2017013C NO2017013I2 (en) | 2002-01-18 | 2017-04-10 | peginterferon beta-1a |
CY20201100115T CY1122841T1 (en) | 2002-01-18 | 2020-02-06 | POLYALKYLENE POLYMERIC COMPOUNDS AND USES THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34991702P | 2002-01-18 | 2002-01-18 | |
US60/349,917 | 2002-01-18 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/892,830 Continuation US8017733B2 (en) | 2002-01-18 | 2004-07-16 | Polyalkylene polymer compounds and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2003061577A2 WO2003061577A2 (en) | 2003-07-31 |
WO2003061577A3 WO2003061577A3 (en) | 2003-10-02 |
WO2003061577A8 true WO2003061577A8 (en) | 2008-11-20 |
Family
ID=27613339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/001559 WO2003061577A2 (en) | 2002-01-18 | 2003-01-17 | Polyalkylene glycol with moiety for conjugating biologically active compound |
Country Status (35)
Country | Link |
---|---|
US (2) | US8017733B2 (en) |
EP (3) | EP3025726B1 (en) |
JP (5) | JP2005526151A (en) |
KR (1) | KR100964411B1 (en) |
CN (2) | CN1630530A (en) |
AU (1) | AU2003210564B2 (en) |
BE (1) | BE2016C040I2 (en) |
BG (1) | BG66525B1 (en) |
BR (1) | BRPI0306993B8 (en) |
CA (4) | CA2753899C (en) |
CY (2) | CY2016027I2 (en) |
CZ (1) | CZ2004877A3 (en) |
DK (2) | DK3025726T3 (en) |
EA (2) | EA009783B1 (en) |
EE (1) | EE05509B1 (en) |
ES (2) | ES2774801T3 (en) |
GE (2) | GEP20074024B (en) |
HK (3) | HK1072721A1 (en) |
HU (4) | HUE047557T2 (en) |
IL (1) | IL163006A (en) |
IS (1) | IS2989B (en) |
LU (1) | LU93162I2 (en) |
ME (2) | MEP35608A (en) |
MX (1) | MXPA04006855A (en) |
NL (1) | NL300826I2 (en) |
NO (3) | NO339857B1 (en) |
NZ (1) | NZ534708A (en) |
PL (2) | PL213322B1 (en) |
PT (1) | PT3025726T (en) |
RS (1) | RS55578B1 (en) |
SI (2) | SI1476181T1 (en) |
SK (1) | SK3102004A3 (en) |
UA (1) | UA82184C2 (en) |
WO (1) | WO2003061577A2 (en) |
ZA (1) | ZA200406555B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8835556B2 (en) | 2002-12-31 | 2014-09-16 | Nektar Therapeutics | Hydrolytically stable maleimide-terminated polymers |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA009783B1 (en) | 2002-01-18 | 2008-04-28 | Байоджен Айдек Ма Инк. | Polyalkylene glycolhaving a moiety for conjugation of a biologically active compound |
US20150246097A9 (en) * | 2002-01-18 | 2015-09-03 | Biogen Idec Ma Inc. | Polyalkylene Polymer Compounds and Uses Thereof |
UA80838C2 (en) | 2002-09-09 | 2007-11-12 | Water-soluble polymer alkanals | |
US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
PL219741B1 (en) * | 2002-12-26 | 2015-07-31 | Mountain View Pharmaceuticals | Polymer conjugates of interferon-beta with enhanced biological potency |
TWI364295B (en) * | 2002-12-26 | 2012-05-21 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
ATE536861T1 (en) | 2003-06-26 | 2011-12-15 | Control Delivery Sys Inc | BIOERODABLE SUSTAINED RELEASE DRUG DELIVERY SYSTEMS |
ES2315680T3 (en) | 2003-06-26 | 2009-04-01 | Psivida Inc. | IN SITU GELIFICATION PHARMACY DISTRIBUTION SYSTEM. |
EP1758583A2 (en) * | 2004-05-31 | 2007-03-07 | Ranbaxy Laboratories Limited | Arylpiperazine derivatives useful as adrenergic receptor antagonists |
US7851565B2 (en) | 2004-12-21 | 2010-12-14 | Nektar Therapeutics | Stabilized polymeric thiol reagents |
US20070004635A1 (en) * | 2005-06-02 | 2007-01-04 | Schering Corporation | Method of treating interferon non-responders using HCV protease inhibitor |
US8268935B2 (en) * | 2005-07-08 | 2012-09-18 | Elan Pharmaceuticals, Inc. | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds |
JP2009538338A (en) * | 2006-05-22 | 2009-11-05 | イーラン ファーマスーティカルズ、インコーポレイテッド | Preparation of polymer complexes of therapeutic, agricultural and food additive compounds |
US20100222546A1 (en) * | 2006-11-28 | 2010-09-02 | David Crich | Methods for the preparation of functionalized peptides, proteins and carbohydrates and their conjugates |
CA2693616A1 (en) * | 2007-07-11 | 2009-01-15 | Enzon Pharmaceuticals, Inc. | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
US20090017004A1 (en) * | 2007-07-11 | 2009-01-15 | Enzon Pharmaceuticals, Inc. | Polymeric drug delivery systems containing an aromatic allylic acid |
CL2008002399A1 (en) * | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c. |
CN103536906A (en) * | 2008-06-05 | 2014-01-29 | 津莫吉尼蒂克斯公司 | Use of pegylated Type III Interferons for the treatment of hepatitis C |
JP5639585B2 (en) * | 2008-07-31 | 2014-12-10 | ファーマエッセンティア コーポレイション | Peptide-polymer conjugate |
GB0823309D0 (en) * | 2008-12-19 | 2009-01-28 | Univ Bath | Functionalising reagents and their uses |
EP2439736A1 (en) | 2009-06-02 | 2012-04-11 | Panasonic Corporation | Down-mixing device, encoder, and method therefor |
UA109646C2 (en) * | 2009-12-10 | 2015-09-25 | THERAPEUTIC APPLICATION OF POLYMER PROTEIN CONJUGATES | |
US20130225789A1 (en) * | 2012-02-29 | 2013-08-29 | Yi Sun | Polyethylene Glycol Having Hetero Multiple Functional Groups |
US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
KR101475630B1 (en) * | 2013-05-31 | 2014-12-22 | 동국대학교 산학협력단 | Composition for the prevention or treatment of Hepatitis C, comprising extracts or fractions of Vitidis Vinferae Radix as an effective ingredient |
US11759500B2 (en) * | 2014-07-24 | 2023-09-19 | Abion Inc. | PEGylated interferon-beta variant |
MX2017002140A (en) * | 2014-08-19 | 2017-08-21 | Biogen Ma Inc | Pegylation method. |
GB201419108D0 (en) | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
KR20230079520A (en) | 2014-11-06 | 2023-06-07 | 파마에센시아 코퍼레이션 | Dosage Regimen for PEGylated Interferon |
ES2831079T3 (en) * | 2017-06-28 | 2021-06-07 | Construction Research & Technology Gmbh | Dispersant for inorganic particles |
US11472894B2 (en) | 2018-07-23 | 2022-10-18 | Carnegie Mellon University | Enzyme-assisted ATRP procedures |
CN109232898A (en) * | 2018-08-02 | 2019-01-18 | 张玲 | A kind of preparation method of the polyimides new material with anticoagulant functions |
CN111534458B (en) * | 2020-04-13 | 2022-01-14 | 浙江工业大学 | Achromobacter TBC-1 and application thereof in degradation of 1,3,6,8-tetrabromocarbazole |
CN113716982B (en) * | 2021-08-24 | 2022-05-06 | 重庆云瑞肥业有限公司 | Fermentation fertilizer making device for recycling food waste |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) * | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
EP0082481B2 (en) | 1981-12-23 | 1990-09-12 | Schering Corporation | Stabilised alpha-interferon formulations and their preparation |
WO1985003934A1 (en) * | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Chemically modified protein and process for its preparation |
GB8334102D0 (en) * | 1983-12-21 | 1984-02-01 | Searle & Co | Interferons with cysteine pattern |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
DE3675588D1 (en) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
JP2524586B2 (en) | 1985-06-26 | 1996-08-14 | シタス コーポレイション | Solubilization of proteins for pharmaceutical compositions utilizing polymer conjugation |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
JP2514950B2 (en) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | Chemically modified protein, its production method and intermediate |
US4894226A (en) * | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5135919A (en) | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5286637A (en) * | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
WO1993012145A1 (en) * | 1991-12-19 | 1993-06-24 | Baylor College Of Medicine | Pva or peg conjugates of peptides for epitope-specific immunosuppression |
ZA933926B (en) * | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5874075A (en) * | 1993-10-06 | 1999-02-23 | Amgen Inc. | Stable protein: phospholipid compositions and methods |
PT730470E (en) | 1993-11-10 | 2002-08-30 | Enzon Inc | IMPROVED INTERFERENCE-POLYMER CONJUGATES |
US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
CA2206852A1 (en) * | 1994-12-07 | 1996-06-13 | Novo Nordisk A/S | Polypeptide with reduced allergenicity |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
SE9503380D0 (en) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
AU730969B2 (en) * | 1995-10-19 | 2001-03-22 | University Of Washington | Discrete-length polyethylene glycols |
US5702717A (en) * | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5747639A (en) * | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
ATE200030T1 (en) | 1997-01-29 | 2001-04-15 | Polymasc Pharmaceuticals Plc | PEGYLATION PROCEDURE |
KR20000075983A (en) | 1997-03-05 | 2000-12-26 | 엘. 데이예를 카렌. | Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication |
US5990237A (en) * | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
US7642323B2 (en) * | 1997-11-06 | 2010-01-05 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US6448369B1 (en) * | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US6180095B1 (en) * | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
JP4465109B2 (en) * | 1997-12-17 | 2010-05-19 | エンゾン ファーマシューティカルズ,インコーポレーテッド | Polymer prodrugs of amino and hydroxyl containing bioactive agents |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
US5965119A (en) * | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
ES2307865T3 (en) * | 1998-03-12 | 2008-12-01 | Nektar Therapeutics Al, Corporation | METHOD FOR PREPARING POLYMERIC CONJUGATES. |
CA2330451A1 (en) * | 1998-04-28 | 1999-11-04 | Applied Research Systems Ars Holding N.V. | Polyol-ifn-beta conjugates |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
ES2630278T3 (en) * | 1998-10-16 | 2017-08-21 | Biogen Ma Inc. | Interferon beta-1a polymer conjugates and uses thereof |
KR100698559B1 (en) * | 1999-06-11 | 2007-03-21 | 넥타르 테라퓨틱스 에이엘, 코포레이션 | Hydrogels derived from chitosan and polyethylene glycol or related polymers |
US7144574B2 (en) * | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
US6531122B1 (en) * | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
BR0013638A (en) | 1999-08-27 | 2002-05-14 | Maxygen Aps | New interferon beta-like molecules |
MXPA02006216A (en) | 1999-12-22 | 2004-02-26 | Nektar Therapeutics Al Corp | Sterically hindered derivatives of water soluble polymers. |
US6413507B1 (en) * | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
US7052686B2 (en) * | 2000-09-29 | 2006-05-30 | Schering Corporation | Pegylated interleukin-10 |
US7053150B2 (en) * | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
TW593427B (en) * | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
BR0206852A (en) * | 2001-02-01 | 2005-05-03 | Biogen Inc | Neublastin polymer conjugates and methods for using them |
YU48703A (en) | 2001-02-27 | 2006-05-25 | Maxygen Aps | New interferon beta-like molecules |
US7009033B2 (en) * | 2001-07-02 | 2006-03-07 | Polymer Source Inc. | Heterofunctional polyethylene glycol and polyethylene oxide, process for their manufacture |
EP2939696B1 (en) * | 2001-10-18 | 2016-03-09 | Nektar Therapeutics | Polymer conjugates of opioid antagonists |
KR20070072924A (en) * | 2001-11-20 | 2007-07-06 | 파마시아 코포레이션 | Chemically-modified human growth hormone conjugates |
US6956135B2 (en) * | 2001-12-11 | 2005-10-18 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
KR100488351B1 (en) * | 2001-12-11 | 2005-05-11 | 선바이오(주) | Novel polyethylene glycol-propionaldehyde derivatives |
AU2002357806A1 (en) * | 2001-12-11 | 2003-06-23 | Sun Bio, Inc. | Novel monofunctional polyethylene glycol aldehydes |
US7041855B2 (en) * | 2001-12-11 | 2006-05-09 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
US6916962B2 (en) | 2001-12-11 | 2005-07-12 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
EA009783B1 (en) | 2002-01-18 | 2008-04-28 | Байоджен Айдек Ма Инк. | Polyalkylene glycolhaving a moiety for conjugation of a biologically active compound |
UA80838C2 (en) | 2002-09-09 | 2007-11-12 | Water-soluble polymer alkanals | |
PL219741B1 (en) * | 2002-12-26 | 2015-07-31 | Mountain View Pharmaceuticals | Polymer conjugates of interferon-beta with enhanced biological potency |
US20110165122A1 (en) * | 2009-11-10 | 2011-07-07 | The Regents Of The University Of California | Method for targeted and sustained antiviral therapy |
-
2003
- 2003-01-17 EA EA200400962A patent/EA009783B1/en active Protection Beyond IP Right Term
- 2003-01-17 PL PL372728A patent/PL213322B1/en unknown
- 2003-01-17 WO PCT/US2003/001559 patent/WO2003061577A2/en active Application Filing
- 2003-01-17 SK SK310-2004A patent/SK3102004A3/en not_active Application Discontinuation
- 2003-01-17 BR BRPI0306993A patent/BRPI0306993B8/en not_active IP Right Cessation
- 2003-01-17 DK DK15203017T patent/DK3025726T3/en active
- 2003-01-17 GE GEAP20038365A patent/GEP20074024B/en unknown
- 2003-01-17 SI SI200332472A patent/SI1476181T1/en unknown
- 2003-01-17 CA CA2753899A patent/CA2753899C/en not_active Expired - Lifetime
- 2003-01-17 GE GEAP8365A patent/GEP20064024B/en unknown
- 2003-01-17 JP JP2003561523A patent/JP2005526151A/en active Pending
- 2003-01-17 MX MXPA04006855A patent/MXPA04006855A/en active IP Right Grant
- 2003-01-17 ME MEP-356/08A patent/MEP35608A/en unknown
- 2003-01-17 PT PT152030177T patent/PT3025726T/en unknown
- 2003-01-17 RS YU63504A patent/RS55578B1/en unknown
- 2003-01-17 EP EP15203017.7A patent/EP3025726B1/en not_active Expired - Lifetime
- 2003-01-17 CN CNA038057972A patent/CN1630530A/en active Pending
- 2003-01-17 HU HUE15203017A patent/HUE047557T2/en unknown
- 2003-01-17 DK DK03731987.8T patent/DK1476181T3/en active
- 2003-01-17 CA CA2473526A patent/CA2473526C/en not_active Expired - Lifetime
- 2003-01-17 KR KR1020047011171A patent/KR100964411B1/en active Protection Beyond IP Right Term
- 2003-01-17 EP EP03731987.8A patent/EP1476181B1/en not_active Expired - Lifetime
- 2003-01-17 CA CA2840490A patent/CA2840490C/en not_active Expired - Lifetime
- 2003-01-17 PL PL397261A patent/PL397261A1/en unknown
- 2003-01-17 EP EP19203313.2A patent/EP3669887A1/en not_active Withdrawn
- 2003-01-17 AU AU2003210564A patent/AU2003210564B2/en active Active
- 2003-01-17 EA EA200701386A patent/EA011829B1/en not_active IP Right Cessation
- 2003-01-17 EE EEP200400105A patent/EE05509B1/en unknown
- 2003-01-17 CA CA2952488A patent/CA2952488C/en not_active Expired - Lifetime
- 2003-01-17 ES ES15203017T patent/ES2774801T3/en not_active Expired - Lifetime
- 2003-01-17 UA UA20040706173A patent/UA82184C2/en unknown
- 2003-01-17 HU HUE03731987A patent/HUE028163T2/en unknown
- 2003-01-17 HU HU0500457A patent/HU230473B1/en unknown
- 2003-01-17 CN CN2009102081892A patent/CN101700401B/en not_active Expired - Lifetime
- 2003-01-17 NZ NZ534708A patent/NZ534708A/en not_active IP Right Cessation
- 2003-01-17 SI SI200332604T patent/SI3025726T1/en unknown
- 2003-01-17 CZ CZ2004877A patent/CZ2004877A3/en unknown
- 2003-01-17 ME MEP-2008-356A patent/ME00239B/en unknown
- 2003-01-17 ES ES03731987.8T patent/ES2566797T3/en not_active Expired - Lifetime
-
2004
- 2004-07-14 IL IL163006A patent/IL163006A/en active Protection Beyond IP Right Term
- 2004-07-15 IS IS7353A patent/IS2989B/en unknown
- 2004-07-16 US US10/892,830 patent/US8017733B2/en active Active
- 2004-08-10 BG BG108839A patent/BG66525B1/en unknown
- 2004-08-17 ZA ZA2004/06555A patent/ZA200406555B/en unknown
- 2004-08-17 NO NO20043422A patent/NO339857B1/en not_active IP Right Cessation
-
2005
- 2005-05-09 HK HK05103877.7A patent/HK1072721A1/en not_active IP Right Cessation
-
2009
- 2009-04-30 JP JP2009110274A patent/JP5275125B2/en not_active Expired - Lifetime
-
2010
- 2010-11-01 HK HK10110235.2A patent/HK1143553A1/en not_active IP Right Cessation
-
2011
- 2011-09-12 US US13/230,080 patent/US8524660B2/en not_active Expired - Lifetime
-
2012
- 2012-07-05 JP JP2012151745A patent/JP2012255156A/en active Pending
-
2013
- 2013-01-21 JP JP2013008426A patent/JP2013136756A/en not_active Abandoned
-
2015
- 2015-07-02 JP JP2015133310A patent/JP6030717B2/en not_active Expired - Lifetime
- 2015-08-26 NO NO20151082A patent/NO344612B1/en not_active IP Right Cessation
-
2016
- 2016-08-03 LU LU93162C patent/LU93162I2/en unknown
- 2016-08-04 BE BE2016C040C patent/BE2016C040I2/fr unknown
- 2016-08-05 CY CY2016027C patent/CY2016027I2/en unknown
- 2016-08-11 NL NL300826C patent/NL300826I2/nl unknown
- 2016-08-18 HU HUS1600035C patent/HUS1600035I1/en unknown
- 2016-10-28 HK HK16112449.4A patent/HK1224185A1/en not_active IP Right Cessation
-
2017
- 2017-04-10 NO NO2017013C patent/NO2017013I2/en unknown
-
2020
- 2020-02-06 CY CY20201100115T patent/CY1122841T1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8835556B2 (en) | 2002-12-31 | 2014-09-16 | Nektar Therapeutics | Hydrolytically stable maleimide-terminated polymers |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003061577A8 (en) | Polyalkylene glycol with moiety for conjugating biologically active compound | |
WO2004110358A3 (en) | Polymeric conjugates for tissue activated drug delivery | |
WO2000064486A3 (en) | Enzymatically activated polymeric drug conjugates | |
ATE349438T1 (en) | CYTOTOXIC ACTIVE INGREDIENTS CONTAINING TAXANES AND THEIR THERAPEUTIC USE | |
CA2910494C (en) | Insulin-oligomer conjugates, formulations and uses thereof | |
ATE344801T1 (en) | CYTOTOXIC AGENTS CONTAINING DOXORUBICIN AND DAUNORUBICIN AND THEIR THERAPEUTIC USE | |
JP2003501486A5 (en) | ||
EP0740650A4 (en) | Codrugs as a method of controlled drug delivery | |
IN2015DN01132A (en) | ||
WO2001092288A3 (en) | Cobalamin compounds useful as antibiotic agents and as imaging agents | |
WO1997029779A3 (en) | EGF-Genistein conjugates for the treatment of cancer | |
WO2001062300A3 (en) | Caspase activated prodrugs therapy | |
EP1698629A3 (en) | Polyamines and their use in therapy | |
HK1075205A1 (en) | Combination of selected opioids with muscarine antagonists for treating urinary incontinence | |
AU6559800A (en) | Use of hyaluronic acid derivatives in pharmaceutical preparations and biomaterials for the prevention and treatment of cutaneous scars | |
WO1990015628A1 (en) | Polymer/antibiotic conjugate | |
CA2444266A1 (en) | Use of bile acid or bile salt fatty acid conjugates | |
WO2001060412A3 (en) | Modification of biopolymers for improved drug delivery | |
EP2275143A3 (en) | Conjugated anti-psychotic drugs and uses thereof | |
SG149685A1 (en) | Polymer conjugates of neublastin and methods of using same | |
US20040186087A1 (en) | Siderophore conjugates of photoactive dyes for photodynamic therapy | |
AU2002700A (en) | Novel depsipeptide compound | |
EP2272537A3 (en) | Salts of conjugated psychotropic drugs and processes of preparing same | |
WO2002049672A3 (en) | Conjugates of antibodies and anticancer drugs | |
WO2001007029A3 (en) | Substituted guanidines and the use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-635/04 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 163006 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/006855 Country of ref document: MX Ref document number: 2473526 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 372728 Country of ref document: PL Ref document number: 10892830 Country of ref document: US Ref document number: 1-2004-501075 Country of ref document: PH Ref document number: 2003561523 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047011171 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3102004 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 108839 Country of ref document: BG Ref document number: 10883903 Country of ref document: BG |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2004-877 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003210564 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003731987 Country of ref document: EP Ref document number: 534708 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/06555 Country of ref document: ZA Ref document number: 2388/DELNP/2004 Country of ref document: IN Ref document number: 200406555 Country of ref document: ZA Ref document number: 200400962 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref country code: GE Ref document number: GE P |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8365 Country of ref document: GE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038057972 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003731987 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2004-877 Country of ref document: CZ |